Barclays Turns Bearish on Janux: Lead Program JANX007 Loses Confidence
Barclays cut Janux Therapeutics to Underweight, citing doubts on JANX007 and limited near-term upside despite long-term potential.
/ 124 items
#XY Analyst Up/Down↓
Barclays Upgrades Celldex to Overweight, Raises Price Target to $45
Barclays boosts Celldex Therapeutics on strong drug outlook; higher success odds and sales expectations.
UBS Sees 6-9% Growth for Amneal: Why the Recent Dip is a Buying Opportunity
UBS starts coverage on Amneal Pharmaceuticals with a Buy rating. Strong specialty growth, Parkinson’s drugs, and attractive entry point after recent selloff.
Lilly’s Foundayo Pill Launches Strong: 1,400 Prescriptions in Week 1
Eli Lilly’s new GLP-1 pill shows strong early demand, big weight loss benefits, and promising heart & diabetes results.
Goldman Sachs Highlights Corvus Pharmaceuticals as a Promising Oral Player in $24 Billion Atopic Dermatitis Market
Goldman sees Corvus as a buy: its oral eczema drug could rival Dupixent and grow into multiple diseases, boosting the stock potential.
Morgan Stanley Sees Big Potential in Kalaris’ Eye Drug TH103
Kalaris Therapeutics gets a boost as Morgan Stanley backs its longer-lasting eye drug, cutting injections for patients.